结核性胸膜炎胸水纤溶活性干预对胸膜增生的影响

目的:探讨结核性胸腔积液的纤溶活性干预和胸膜增生的关系。方法:对85例结核性胸腔积液患者随机分组,试验组使用重组组织型纤溶酶原激活剂(rt-PA)胸腔内注射进行干预,两组分别测定试验前和一月后胸膜厚度进行比较。结果:两组患者治疗前胸膜厚度无显著性差异(P>0.05)而试验组治疗后胸膜增厚程度明显低于对照组(P<0.001)。结论:胸水纤溶活性的失衡与胸膜纤维化形成密切相关。胸腔内注射纤溶药物对减轻胸膜纤维化、保护肺功能有较高的辅助治疗价值。

Objectives： To study relationship between to intervene fibrinolytic activity and pleural hyperplasia in the patients with tuberculous pleurisy. Methods： 85 cases of the patients with tuberculous pleurisy are random divided into test group and comparison group. The patient＇ s pleura thickness both groups are measured for comparison at begin and after one month. The rt - PA are injected into chest cavity of patients of test group for treatment. Results： There was no signifi- cant difference in patient＇s pleura thickness both groups before treatment （ P 〉 0. 05 ）. But the pleura thickness of test groups is thicker of comparison group（ P 〈 0. 0001 ）. Conclusion ：The fibrinolytic activity of pleural fluid closely contacts with pleural thick- ness. Injecting rt - PA into chest cavity may be decrease pleural finrosis and regard to lungs function of patients with tuberculous pleurisy.